Interestingly, IgG3 anti-gp120 antibodies were detected more frequently in the non-progressor than in the progressor group [73] and, in a case-control study in the RV144 trial, higher V1/V2 specific anti-Env IgG3 responses correlated with a decreased risk of infection acquisition [81]. Here, ERVW-1 is linked to infection.